


بسم الله الرحمن الرحيم





شبكة المعلومات الجامعية التوثيق الالكتروني والميكروفيلم



جامعة عين شمس

التوثيق الإلكتروني والميكروفيلم


قسم

نقسم بالله العظيم أن المادة التي تم توثيقها وتسجيلها
علي هذه الأقراص المدمجة قد أعدت دون أية تغيرات




يجب أن

تحفظ هذه الأقراص المدمجة بعيدا عن الغبار






بعض الوثائق الأصلية تالفة





بالرسالة صفحات لم ترد بالأصل



B12072

DEVELOPMENT AND ADAPTATION OF SUITABLE METHODOLOGY FOR QUALITY ASSURANCE OF CERTAIN DRUGS

A Thesis Presented By
Riad A. El Barbary
(B. Pharm. Sciences)

**In the Partial Fulfillment of the
Requirements for the Degree**

**Master of pharmaceutical Sciences
(Pharmaceutical Chemistry)**

**Department of Pharmaceutical Chemistry
Faculty of Pharmacy
Tanta University
Tanta
Egypt
2003**

بِسْمِ اللَّهِ الرَّحْمَنِ الرَّحِيمِ

(قَالُوا سُبْحَانَكَ لَا عِلْمَ لَنَا إِلَّا مَا عَلَّمْتَنَا إِنَّكَ

أَنْتَ الْعَلِيمُ الْحَكِيمُ)

مصدق الله العظيم

سورة البقرة (٣٢)

Supervisory Committee

1. **Prof. Dr. Mohamed A. El-Dawy**; Professor of Pharmaceutical Chemistry, Department of Pharmaceutical Chemistry, Faculty of Pharmacy, Tanta University.
2. **Prof. Dr. Mokhtar M. Mabrouk**; Professor of Pharmaceutical Analytical Chemistry and Vice Dean of Graduate Studies and Research, Faculty of Pharmacy, Tanta University.

Approval Sheet

The thesis has been approved by the examination committee on Aug. 3, 2003 by:-
Signature

1. Prof. Dr. El-Sebai A. Ibrahim

Professor of Pharmaceutical Chemistry,.....*El-Sebai*
Department of Pharmaceutical Chemistry,.....
Faculty of Pharmacy, Alexandria University.....

2. Prof. Dr. Mohamed A. El-Dawy

Professor of Pharmaceutical Chemistry,.....*M. A. El-Dawy*
Department of Pharmaceutical Chemistry,.....
Faculty of Pharmacy, Tanta University.....*8/3/03*

3. Prof. Dr. Hassan H. Farag

Professor of Pharmaceutical Chemistry,.....*H. Farag*
Department of Pharmaceutical Chemistry,.....
Faculty of Pharmacy, Assiut University.....

4. Prof. Dr. Mokhtar M. Mabrouk

Professor of Pharmaceutical Analytical Chemistry,.....*M. Mabrouk*
Vice Dean of Graduate Studies and Research,.....
Faculty of Pharmacy, Tanta University.....

To My Father,

Mother and

My Sisters

TABLE OF CONTENTS

	<i>Page</i>
ACKNOWLEDGEMENT	II
SCOPE OF THE INVESTIGATION	III
LIST OF ABBREVIATIONS	V
LIST OF FIGURES	VII
LIST OF TABLES	X
 Part (I): Warfarin Sodium	
Introduction	2
Literature review	3
Experimental	5
Results and Discussion	8
 Part (II): Pentoxifylline	
Introduction	30
Literature review	30
Experimental	31
Results and Discussion	34
 Part (III): Propafenone Hydrochloride	
Introduction	47
Literature review	47
Experimental	49
Results and Discussion	52
 Part (IV): Acebutolol Hydrochloride	
Introduction	64
Literature review	64
Experimental	66
Results and Discussion	70
 REFERENCES	81
ENGLISH SUMMARY	91
ARABIC SUMMARY	94

Acknowledgment


I wish to express all my cordial gratitude and faithful thankfulness to my **Professor Mohamed A. El Dawy**; professor of pharmaceutical chemistry, department of pharmaceutical chemistry, faculty of pharmacy, Tanta university, for suggesting the research topic, for his continuous guidance and sensible encouragement during the course of this research and for his endurance during the preparation of the manuscript.

I feel deeply beholden and sincerely obliged to **Professor Mokhtar M. Mabrouk**; professor of pharmaceutical analytical chemistry and vice dean of graduate studies and research, faculty of pharmacy, Tanta university for his serviceable advices and worthy incitement during all the stages of this research project.


The prominent role of **GlaxoSmithKline (GSK)**, Cairo, Egypt and **Alexandria Pharmaceutical Co.**, Alexandria, Egypt in providing the raw materials required for this research project is highly appreciated.

Scope of the Investigation


The thesis at hand constitutes a part of a program directed toward facing certain challenges that pharmacy practice encounters during both clinical and industrial settings ⁽¹⁻⁶⁾. The scope of this manuscript utilizes the built-in high sensitivity of spectrofluorimetric analysis technique to develop and adapt quality assurance (QA) algorithms to solve different problems imposed by said challenges. Life saving drugs, containing active methylene groups and having narrow therapeutic indices, namely warfarin sodium, pentoxifylline, propafenone hydrochloride and acebutolol hydrochloride, continue to face such problems during their manufacture and utilization. Accordingly, addressing these problems formulates the subject matter of this research project.




Warfarin



Pentoxifylline



Propafenone hydrochloride



Acebutolol hydrochloride

Warfarin is the most problematic of these drugs because of its marked low dose and its individualized pharmacokinetics. This calls upon finding a high sensitive analytical method that would be suitable for content uniformity and dissolution QA methods during manufacture. Further, the method to be developed will have to be suitable for titration of patients' response to anticoagulant therapy and minimization of the shortcomings of the international normalized ratio (INR) system in clinical settings. Furthermore, its wide use as a rodenticide requires the availability of validated method for determination of trace amounts as a pollutant and measurement of its blood level in case of suspected poisoning.

Pentoxifylline is marketed as controlled release dosage forms and propafenone is currently being studied for such dosage forms. Accordingly, the method to be developed for these two drugs will be adapted for rate of release measurements for such dosage forms.

All these drugs do not require dedicated line for their manufacture. Accordingly, there is a need for determination of ultra trace amounts of each drug during validation of equipment cleaning prior to line clearance, a mandatory regulation in order to avoid cross contamination.

The validity of the methods to be developed will be tested for compliance with current good laboratory practice (cGLP) as stipulated by leading regulatory competent authorities at national (e.g. EPA, FDA and OSHA), regional (e.g. EMEA), and international (e.g. ICH and WHO) levels.

List of Abbreviations

ADCo	: The Arab Drugs Company (Egypt).
AMP	: Adenosine Mono-Phosphate.
ATP	: Adenosine Tri-Phosphate.
BSA	: Bovine Serum Albumin.
cGLP	: Current Good Laboratory Practice.
CNS	: Central Nervous System.
CV	: Coefficient of Variation.
CZE	: Capillary Zone Electrophoresis.
DVT	: Deep Vein Thrombosis.
EIMS	: Electron Ionization Mass Spectrometry.
EMEA	: European Medicines Evaluation Agency (EU).
EPA	: Environmental Protection Agency (USA).
FDA	: Food and Drug Administration (USA).
GC	: Gas Chromatography.
Gm	: Gram.
GSK	: GlaxoSmithKline.
HPLC	: High Performance Liquid Chromatography.
Hr	: Hour.
HSA	: Human Serum Albumin.
ICH	: International Conference on Harmonization (EU, Japan, and USA).
INR	: International Normalized Ratio.
ISA	: Intrinsic Sympathomimetic Activity.
ISI	: International Sensitivity Index.
LC	: Liquid Chromatography.
LC-MS	: Liquid Chromatography-Mass Spectrometry.
LOD	: Limit of Detection.
LOQ	: Limit of Quantitation.